- Home
- FFIV vs NBIX Comparison
FFIV vs NBIX Comparison
Compare FFIV & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FFIV | NBIX |
|---|---|---|
| Founded | 1996 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 13.9B |
| IPO Year | 1999 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FFIV | NBIX |
|---|---|---|
| Price | $287.11 | $129.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 22 |
| Target Price | ★ $305.50 | $175.23 |
| AVG Volume (30 Days) | 566.6K | ★ 1.3M |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.56 | ★ 41.95 |
| EPS | 3.10 | ★ 4.67 |
| Revenue | ★ $3,088,072,000.00 | $161,626,000.00 |
| Revenue This Year | $8.00 | $22.85 |
| Revenue Next Year | $3.27 | $9.99 |
| P/E Ratio | $91.89 | ★ $27.36 |
| Revenue Growth | 9.66 | ★ 977.51 |
| 52 Week Low | $223.76 | $84.23 |
| 52 Week High | $346.00 | $160.18 |
Technical Indicators
Market Signals| Indicator | FFIV | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 57.21 | 44.57 |
| Support Level | $284.47 | $129.17 |
| Resistance Level | $303.03 | $137.37 |
| Average True Range (ATR) | 8.52 | 3.11 |
| MACD | 0.78 | 0.18 |
| Stochastic Oscillator | 89.22 | 40.12 |
Price Performance
Historical ComparisonAbout FFIV F5 Inc.
F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.